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Evolved Aliphatic Halogenases Enable Regiocomplementary C-H 
Functionalization of an Added-Value Chemical 
Takahiro Hayashi,[a] Mathieu Ligibel,[b] Emine Sager,[b] Moritz Voss,[a] Jürg Hunziker,[b] Kirsten 
Schroer,[b] Radka Snajdrova,[b] and Rebecca Buller*[a] 
Abstract: Non-heme iron halogenases represent synthetically 
valuable biocatalysts that are capable of halogenating unactivated 
sp3-hybridized carbon centers with exquisite stereo- and 
regioselectivity. The reported substrate scope of these enzymes, 
however, is limited primarily to the natural substrates and their 
analogues. Here we engineered the recently discovered halogenase 
WelO5* for chlorination of a pharmaceutically interesting martinelline-
derived fragment. Using structure-guided evolution, a halogenase 
variant with a more than 290-fold higher total turnover number and a 
400-fold higher apparent kcat compared to the wildtype enzyme was 
generated. Moreover, we identified key positions in the active site 
which allowed directing the halogen to different positions in our target 
substrate. This report provides the first example of enzyme 
engineering to expand the substrate scope of a non-heme iron 
halogenase beyond the native indole alkaloid-type substrates. The 
highly evolvable nature of WelO5* underscores the usefulness of this 
enzyme family for the late-stage halogenation of value-added 
chemicals.  
The selective installation of a halogen atom into an 
unactivated, aliphatic sp3 carbon center is synthetically useful for 
the production of high-value chemicals, including 
pharmaceuticals and agrochemicals.[1] The substitution of a 
hydrogen with a halogen atom alters the molecule’s properties 
and may affect the molecule’s metabolism and pharmacokinetic 
profile. In addition, C-X motifs represent useful synthetic handles 
for the modification of the molecule in further chemical steps. 
Traditionally, haloalkanes are prepared through synthetic 
approaches involving functional group transformation using 
corresponding alcohols,[2] alkenes,[3] and acids.[4] Modern 
approaches include light-driven[5], and rare metal-catalyzed 
reactions.[6] However, these methods generally suffer from lack of 
stereoselectivity and have specific demands on the substrate 
structure.[5c, 6c] In contrast, (chemo)-enzymatic methods of 
halogenation need only mild ambient conditions in aqueous 
reaction media and often exhibit excellent regio- and 
stereoselectivity, providing new opportunities to overcome the 
hurdles imposed by the conventional methods.[7] 
The recently discovered aliphatic halogenases AmbO5, 
WelO5 and WelO5* belong to the family of iron/α-ketoglutarate 
(Fe/α-KG) dependent oxygenases and are the only known 
members of this enzyme class capable of acting on freestanding 
substrates.[8] These enzymes share an overall high sequence 
identity (> 79%), whereas WelO5 and WelO5* stem from different 
isolates of the same organism named Hapalosiphon welwitschii 
and differ only by 15-amino acids (Figure S1).[8d, 9] In nature, these 
enzymes catalyze the installation of chlorine atoms into several 
complex indole alkaloids (Scheme 1).[9] The catalytic mechanism 
involves the generation of a high valent FeIV=O intermediate 
which abstracts a hydrogen atom from the substrate to yield a 
carbon radical (Figure S2). The carbon radical is then coupled to 
the iron coordinated chlorine (rather than the hydroxyl), affording 
the corresponding chlorinated compound in a regio- and 
stereoselective manner.[10] Despite the remarkable catalytic 
properties of these enzymes, non-heme iron halogenases have 
not yet been exploited for the chemical transformation of non-
indole alkaloid-type substrates. Thus, to expand the biocatalyst 
toolbox available for aliphatic halogenations, we employed protein 
engineering approaches to create enzymes capable of catalyzing 
the chemically challenging sp3 halogenation of complex 
molecules beyond the natural substrate scope. 
 
 
 
 
 
 
 
Scheme 1. Halogenation of 12-epi-hapalindole C catalyzed by WelO5 and 
AmbO5. 
Taking a first step in this direction, we report the evolution 
of the recently described non-heme iron halogenase WelO5* from 
Hapalosiphon welwitschii IC-52-3[8d] for selective halogenation of 
substrate 1, an analogue of the martinelline core structure[11] 
(Figure 1a), for use in medicinal chemistry. While martinelline is a 
potent bradykynin receptor agonist, anticancer activity of the 
structurally related substrate 1 and some analogues were 
reported.[12] 
Exploiting WelO5*’s promiscuous activity toward the target 
substrate, we optimized its halogenation activity using structure-
guided directed evolution. Within two evolutionary rounds, we 
engineered a set of two regio-complementary halogenases 
capable of producing distinct chlorinated compounds (i.e., 1a and 
1b) with exquisite regio- and stereoselectivity (Figure 1a). 
Simultaneously, we improved the apparent kcat and total turnover 
number (TTN) of the enzyme by more than 400- and 290-fold, 
respectively, compared to the starting variant. These results 
demonstrate the highly evolvable nature of the non-heme iron 
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halogenase WelO5* and highlight the value of this class of 
enzymes for selective halogenation of small molecules.  
To identify a suitable starting scaffold for evolution, a panel 
of recombinant carrier-protein independent “stand-alone” aliphatic 
halogenases (WelO5, AmbO5, WelO5*, and an engineered SadA 
variant[13]), overexpressed in E.coli BL21 (DE3), were used for 
crude cell-lysate biotransformations of the martinelline-derived 
fragment 1 in a deep well plate. While no halogenase activity 
toward the target substrate was detected for WelO5, AmbO5, and 
the SadA variant, the liquid chromatography coupled to mass 
spectrometry (LC-MS) analysis of the biotransformation with 
WelO5* showed formation of two prominent products with m/z 
ratios of 278.2 and 296.1, consistent with the calculated mass of 
a hydroxylated and a chlorinated product of 1, respectively (Figure 
S3). The structures of the chlorinated product 1a and 
hydroxylated product 2a were solved using nuclear magnetic 
resonance (NMR) analysis confirming chlorination and 
hydroxylation of aliphatic carbon centers of 1 (Figure 1a, Table 2). 
It is noteworthy that although wildtype WelO5* exhibited 
promising stereo- and regioselective halogenation activity toward 
the unnatural substrate 1, reaction selectivity of the enzyme (i.e., 
halogenation vs hydroxylation) was low and the hydroxylated 
compound 2a was generated in significant amount (~40%, as 
compared to ~1% yield for the chlorinated product 1a). 
Interestingly, the biotransformation of 12-epi-hapalindole C, which 
has been described as a native substrate of WelO5*,[8d] led to the 
formation of a similar amount of hydroxylated product (~50%) 
besides the desired chlorinated product 12-epi-hapalindole E 
(~25%, Scheme 1 and Figure S4). This low reaction selectivity 
displayed by WelO5* for at least some of its accepted substrates 
was not unexpected. A previous study on SyrB2, a carrier-protein 
dependent aliphatic halogenase, demonstrated that the reaction 
selectivity of this class of enzymes is sensitive to even subtle 
chemical modifications of their native substrates.[14] Based on the 
characterization of the FeIV=O intermediate in SyrB2 by 
Mössbauer, Fe K-edge XAS, and EXFAS spectroscopies[10b] in 
combination with computational analysis,[15] chlorination versus 
hydroxylation selectivity was deduced to be governed by the 
orientation of the substrate with respect to the HO-Fe-Cl plane 
leading to either the Cl- or OH- rebound (Figure S2). 
 To generate a synthetically useful biocatalyst for the late 
stage-functionalization of the martinelline-derived fragment 1, we 
employed structure-guided directed evolution to improve the 
chlorination activity of WelO5*. To that end, our target substrate 
was docked into the iron-binding site of WelO5, a close 
homologue of WelO5* with 95% sequence identity (Figure S1), 
using the Chimera AutoDock Vina tool (Figure 1b).[16] This led to 
the identification of nine residues for individual optimization by 
site-directed saturation mutagenesis using NNK codons. Each 
library was evaluated using a crude cell-lysate assay in a 96-well 
plate format. Out of the nine libraries screened, three libraries 
(A82, A88, and R153) included variants with a moderate (3 to 5-
fold) increase in halogenation activity and two libraries (V81 and 
I161) comprised variants with significant (10- to 20-fold) 
improvement in activity compared to the wildtype variant (Figure 
2 and 3a). Promising hits were collected and characterized by 
gene sequencing, identifying mutations beneficial for the 
halogenation activity (Figure 2). 
 
 
 
 
 
Figure 1. a) Regio-complementary chlorination of a martinelline-derived 
fragment mediated by WelO5* variants and b) a substrate-docked model of 
WelO5 (PDB ID: 5iqt). The residues differing between WelO5 and WelO5* are 
highlighted in green. The red spheres indicate the residues targeted for 
randomization. c) Zoom-in view of the active site of the substrate-docked model. 
While screening the individual libraries, we observed the 
formation of an alternative chlorinated product 1b, which was 
evidenced by the shifted retention time in the LC chromatogram 
compared to product 1a (Figure S8b). NMR analysis of the new 
species confirmed installation of the Cl functional group at an 
alternative sp3 carbon center (product 1b in Figure 1a). 
Interestingly, product 1b was exclusively generated by variants in 
which positions V81 and I161 had been mutated, suggesting that 
these positions serve as regioselectivity switches and dictate 
formation of either chlorination product 1a or 1b (Figure 2) 
depending on amino acid substitution. By plotting the relationship 
of halogenation activity and selectivity (formation of product 1a vs 
1b) of the variants screened (Figure 2), two biocatalysts CA1 
(V81L) and CB1 (I161S) were identified which exhibited improved 
activity and high selectivity to produce halogenated compounds 
1a and 1b, respectively (Table 1). Notably, the evolved variants 
showed increased chlorination activity while the hydroxylation 
activity was not impacted or, in some cases, even diminished, 
thus simultaneously increasing reaction selectivity (Figure S5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Relationship of chlorination activity and selectivity of variants 
screened in the first round. The activity was based on crude-cell lysate assays 
and normalized to the wildtype. The mutations in selected variants are 
annotated. 
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Figure 3. a) Mutational “hot spots” identified in this study (yellow: 3- to 5-fold 
improvement, green: 10- to 20-fold improvement) b) evolutional trajectory of the 
evolved variants CA2 and CB2. 
 
Intrigued by these results, the halogenase WelO5* was 
separately evolved for the two chlorination reactions. Iterative 
saturation mutagenesis (ISM)[17] was employed to improve the 
efficiency of variant CA1. Full randomization of residues 88, 153, 
and 161 by site-directed saturation mutagenesis afforded one 
variant with improved chlorination activity towards 1a. 
Interestingly, variant V81L_I161M, dubbed CA2, also exhibited 
shifted hydroxylation regioselectivity and produced two new 
hydroxylated products, the diastereoisomers 2b (~31%) and 2c 
(~5%), in which the hydroxylation occurred on the same sp3 
carbon as the halogenation (Table 2). The variant CA2 was 
subsequently produced, purified and analysed in vitro showing a 
further 10-fold improvement in the halogenation activity compared 
to variant CA1 (Table 1). Despite the achieved overall 
improvements of reaction selectivity and of the apparent kcat (12- 
and 16-fold, respectively), it should be noted that the evolved 
halogenase variant CA2 still transforms substrate 1 
predominantly into hydroxylated products (Table 2). While the 
amount of halogenated product generated by CA2 is sufficient for 
medicinal chemistry studies,[18] additional optimization of the 
enzyme will be necessary to further expand its application scope. 
A simultaneous two-site randomization was performed to 
further improve variant CB1 for the selective production of 1b. A 
library was constructed using a degenerate SKA codon at position 
81 and a VNT codon at position 161. In crude cell-lysate 
biotransformations, the best variant V81R_I161S, named CB2, 
showed nearly complete consumption of substrate 1 and 
corresponding formation of 1b, while the undesired hydroxylation 
reaction was further minimized (<5%). Subsequent in vitro 
analysis of purified CB2 exhibited a significantly improved 
apparent kcat of up to 400-fold and a more than 290-fold higher 
TTN compared to the wildtype (Figure 3b, Table 1). Furthermore, 
recording of the Michaelis–Menten plot of CB2 showed improved 
enzyme kinetic parameters for the halogenation of substrate 1 
(KM = 0.67 mM, kcat = 3.0 min-1), which are similar to those 
displayed by the wildtype enzymes acting on the native substrates 
(Figure S9d).[9] 
Following our enzyme engineering campaign, we explored 
the capability of the most active evolved variant (CB2) to install 
other halogens into 1. Introduction of alternative halogen salts 
(500 mM NaBr, NaI, or NaF) instead of NaCl into the reaction 
mixture was carried out to determine anion promiscuity. While 
iodine and fluoride were not accepted, presumably due to sterical 
and electronic reasons, incubation with the bromide salt 
generated a product with a m/z ratio of 340.0 consistent with the 
calculated mass of the brominated compound (Figure S6). Overall, 
however, the enzyme prefers the smaller chloride anion (Figure 
S6a) as evidenced by the predominant formation of 1b even in 
the presence of excess NaBr, in line with reported results for the 
SadA variant[13] and WelO5.[19] 
To assess the practical applicability of the evolved variants 
to synthesize value-added compounds for medicinal chemistry, 
the biocatalytic reaction was scaled up using an increased 
substrate load. Chlorination of substrate 1 at 10 mM substrate 
concentration using crude cell-lysate of the evolved variant CB2 
afforded 95% conversion into 1b (Figure S10). Notably, no major 
side product (i.e., hydroxylation or other halogenation product) 
was observed for this variant. The non-optimized preparative 
experiments with variant CA2 (108 mg substrate 1, final 
concentration 2 mM) and CB2 (43.2 mg substrate 1, final 
concentration 2 mM) led to isolated yields of 6% (7.7 mg) for 
product 1a and 30% (14.4 mg) of product 1b, respectively, 
generating sufficient amounts for structure-activity relationship 
(SAR) studies.[18] While further catalyst and process optimization 
are required, these results demonstrate the possibility to evolve 
non-heme iron halogenases such as variant CB2 for the synthesis 
of the chlorinated martinelline fragment 1b. 
Recent efforts to exploit halogenases for the selective 
halogenation of unnatural substrates have been focused primarily 
on flavin-dependent aromatic halogenases.[20] In this report, we 
outline the evolution of WelO5*, a non-heme iron dependent 
halogenase, for the selective halogenation of unactivated, 
aliphatic sp3 carbon centers in the non-natural substrate 1. With 
the introduction of only two mutations, the apparent kcat and TTN 
number for halogenation of the martinelline-derived fragment 
could be improved by two orders of magnitude, highlighting that 
modulation of substrate scope and regioselectivity in WelO5* 
does not necessarily rely on complex, synergistic arrays of 
functional residues that may limit evolvability. In addition, our 
results attest to the malleability of non-heme iron halogenases for 
regiochemical reprogramming while maintaining their high 
enantioselectivity, suggesting that the construction of an ‘enzyme 
 
Table 1. in vitro assay results of wildtype and evolved variants of WelO5*. 
Variant  
(mutation) TTN 
rel. 
TTN 
app. kcat 
/ min-1 
rel. 
app. kcat 
WT 0.11 ± 0.02 1 0.0045 ± 0.0005 1 
CA1 
(V81L) 0.63 ± 0.08 5 0.024 ± 0.003 5 
CA2 
(V81L, I161M) 5.6 ± 0.6 51 0.073 ± 0.008 16 
CB1 
(I161S) 1.6 ± 0.2 14 0.08 ± 0.02 17 
CB2 
(V81R, I161S) 32.9 ± 1.1 299 1.83 ± 0.09 407 
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toolbox’ for aliphatic halogenations is achievable. Interestingly, 
the initial low reaction selectivity, i.e. low halogenation versus 
hydroxylation ratio, could be improved by more than 200-fold 
during evolution. Our most active variant CB2 showed 
significantly reduced hydroxylation activity (<5%) indicating the 
introduction of structural elements that may facilitate the chlorine 
rebound (over hydroxyl rebound) to the target carbon radical. 
While the detailed mechanism behind the improved regio- and 
reaction selectivity of the evolved variants remains unclear, we 
attempted to shed light on the selectivity governing factors by 
carrying out a docking study using the available crystal structure 
of WelO5 (PDB ID: 5IQT), a close homologue of WelO5*, with 
substrate 1. Taking into consideration available literature data,[10b, 
14] our docking study suggests that substrate positioning with 
respect to the iron-oxo and the Cl/OH ligands dictates both, 
regioselectivity and reaction selectivity. Two major substrate 
binding modes were observed: While wildtype halogenation at 
C12 is well predicted by binding mode A, hydroxylation by WelO5* 
seems more likely to occur in binding mode B (Figure S11). The 
set of mutations acquired in CA2 presumably improved 
regioselectivity by favoring binding mode A and slightly shifting 
the substrate toward the iron center, allowing H-abstraction from 
a single C-H bond, namely C12, instead of at two different 
positions as observed for the wildtype enzyme. In fact, both the 
chlorinated product 1a and the major hydroxylated product 2b 
show the same regio- and stereoselectivity (Table 2). CB variants, 
on the other hand, show chlorination activity consistent with the 
binding mode B (Figure S11c). The key mutation I161S, which 
was acquired during the first round of evolution, is assumed to 
stabilize this binding mode facilitating the efficient H-atom 
abstraction on the tertiary carbon center C9. The high reaction 
selectivity of variant CB2 can potentially be ascribed to a 
combination of the substrate positioning and the inherent 
reactivity of Cl over OH.[21] 
To gain further insight into the improved activity of the evolved 
variants, we additionally performed homology modelling using I-
TASSER.[22] Comparison of the starting variant with the evolved 
variant CB2 (V81R_I161S) showed that the replacement of 
isoleucine with serine at position 161 significantly widened the 
active site pocket, presumably facilitating substrate access 
(Figure S12). 
Total turnover numbers of non-heme iron halogenases are 
reportedly low due to auto-oxidative inactivation. The carrier-
protein dependent SyrB2, for example, has been shown to only 
catalyze 7 ± 2 turnovers on its native substrate L-Thr-S-SyrB1 
prior to inactivation,[23] CmaB is active for 16  ± 6 turnovers on its 
substrate L-allo-Ile-S-CmaD,[24] while the free-standing 
halogenase WelO5 exhibits approximately 75 turnovers in the 
biotransformation of its native substrate.[8a] In this study we 
present that enzyme engineering allows to create halogenase 
variants with “natural” catalytic performance albeit for non-natural 
substrates (CA2: 5.6 ± 0.1 turnovers, CB2: 32.9 ± 1.1 turnovers, 
Table 1). During only two rounds of evolution the total turnover 
numbers of CA2 and CB2 could be increased by 50- and 300-fold, 
respectively, boding well for the expansion of the halogenases’ 
application scope as straightforward reshaping of the active site 
was sufficient to enhance the precise functioning of the catalytic 
machinery.  
Future efforts to understand the underlying mechanisms for 
halogenation of non-native substrates will focus on the structural 
analysis of the evolved variants which display improved activity 
toward selective halogenation reactions. Such efforts could lead 
to general engineering principles for this emerging class of 
enzymes and thus enable selective late-stage halogenation of 
traditionally difficult-to-derivatize target substrates.  
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Beyond natural substrates: A protein 
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selective halogenation of a value-
added chemical. Directed evolution of 
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afforded a variant with an up to 400-
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